AngioDynamics Announces American Medical Association’s CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver
AngioDynamics, Inc. (NASDAQ: ANGO) announced that Irreversible Electroporation (IRE) has received CPT® Category I codes for treating lesions in the prostate and liver. This decision by the American Medical Association's CPT® Editorial Panel will facilitate reimbursement for healthcare providers performing IRE ablation procedures and expand access to the NanoKnife System for patients. The new codes will be effective, with physician Relative Value Units (RVUs) attached, on January 1, 2026.
The NanoKnife System uses IRE technology to destroy targeted cells without thermal energy by delivering high-voltage pulses. This minimally invasive treatment offers advantages over traditional surgery or thermal ablation techniques. The CPT® Category I status is a significant milestone for the NanoKnife System, highlighting the value of AngioDynamics' strategic investments in IRE technology.
AngioDynamics, Inc. (NASDAQ: ANGO) ha annunciato che la Elettroporazione Irreversibile (IRE) ha ricevuto i codici CPT® Categoria I per il trattamento delle lesioni nella prostata e nel fegato. Questa decisione del CPT® Editorial Panel dell'American Medical Association faciliterà il rimborso per i fornitori di assistenza sanitaria che eseguono procedure di ablazione IRE e amplierà l'accesso al Sistema NanoKnife per i pazienti. I nuovi codici saranno effettivi, con relativi Valori Unici per i Medici (RVUs), a partire dal 1 gennaio 2026.
Il Sistema NanoKnife utilizza la tecnologia IRE per distruggere cellule mirate senza energia termica, tramite l'emissione di impulsi ad alta tensione. Questo trattamento minimamente invasivo offre vantaggi rispetto alla chirurgia tradizionale o alle tecniche di ablazione termica. Lo status di Categoria I CPT® rappresenta un traguardo significativo per il Sistema NanoKnife, evidenziando il valore degli investimenti strategici di AngioDynamics nella tecnologia IRE.
AngioDynamics, Inc. (NASDAQ: ANGO) anunció que la Electroporación Irreversible (IRE) ha recibido códigos CPT® Categoría I para el tratamiento de lesiones en la próstata y el hígado. Esta decisión del Panel Editorial CPT® de la Asociación Médica Americana facilitará el reembolso para los proveedores de atención médica que realicen procedimientos de ablación IRE y ampliará el acceso al Sistema NanoKnife para los pacientes. Los nuevos códigos serán efectivos, con Unidades Relativas de Valor (RVUs) para médicos, a partir del 1 de enero de 2026.
El Sistema NanoKnife utiliza tecnología IRE para destruir células estudiadas sin energía térmica, mediante la entrega de pulsos de alta tensión. Este tratamiento mínimamente invasivo ofrece ventajas sobre la cirugía tradicional o las técnicas de ablación térmica. El estatus de Categoría I CPT® es un hito significativo para el Sistema NanoKnife, destacando el valor de las inversiones estratégicas de AngioDynamics en tecnología IRE.
AngioDynamics, Inc. (NASDAQ: ANGO)는 비가역적 전기화(IRE)가 전립선 및 간의 병변 치료를 위한 CPT® 1급 코드를 받았다고 발표했습니다. 이 미국 의학 협회의 CPT® 편집 위원회의 결정은 IRE 절제 절차를 시행하는 의료 제공자에 대한 재정 지원을 용이하게 하고, 환자들을 위한 NanoKnife 시스템의 접근성을 확대할 것입니다. 새로운 코드는 2026년 1월 1일부터 의사 상대 가치 단위(RVUs)가 첨부되어 유효할 것입니다.
NanoKnife 시스템은 높은 전압의 펄스를 전달하여 열 에너지 없이 목표 세포를 파괴하는 IRE 기술을 사용합니다. 이 최소 침습적 치료법은 전통적인 수술 또는 열 절제 기술에 비해 장점을 제공합니다. CPT® 1급 상태는 NanoKnife 시스템에 대한 중요한 이정표로, AngioDynamics의 IRE 기술에 대한 전략적 투자 가치를 강조합니다.
AngioDynamics, Inc. (NASDAQ: ANGO) a annoncé que l'électroporation irréversible (IRE) a reçu les codes CPT® Catégorie I pour le traitement des lésions dans la prostate et le foie. Cette décision du Comité Éditorial des CPT® de l'American Medical Association facilitera le remboursement pour les professionnels de la santé réalisant des procédures d'ablation IRE et élargira l'accès au système NanoKnife pour les patients. Les nouveaux codes entreront en vigueur, avec des unités de valeur relative (RVUs) pour les médecins, à partir du 1er janvier 2026.
Le système NanoKnife utilise la technologie IRE pour détruire des cellules ciblées sans énergie thermique en délivrant des impulsions à haute tension. Ce traitement peu invasif offre des avantages par rapport à la chirurgie traditionnelle ou aux techniques d'ablation thermique. Le statut de catégorie I CPT® est une étape importante pour le système NanoKnife, soulignant la valeur des investissements stratégiques d'AngioDynamics dans la technologie IRE.
AngioDynamics, Inc. (NASDAQ: ANGO) hat angekündigt, dass die irreversible Elektroporation (IRE) CPT® Kategorie I-Codes für die Behandlung von Läsionen in der Prostata und der Leber erhalten hat. Diese Entscheidung des CPT®-Redaktionsteams der American Medical Association wird den Rückerstattungsprozess für Gesundheitsdienstleister, die IRE-Ablationsverfahren durchführen, erleichtern und den Zugang zum NanoKnife-System für Patienten erweitern. Die neuen Codes werden ab dem 1. Januar 2026 wirksam sein, mit den zugehörigen relativen Wert-Einheiten (RVUs) für Ärzte.
Das NanoKnife-System nutzt IRE-Technologie, um gezielte Zellen ohne thermische Energie durch Hochspannungspulse zu zerstören. Diese minimal-invasive Behandlung bietet Vorteile gegenüber herkömmlicher Chirurgie oder thermischen Ablationstechniken. Der CPT® Kategorie I-Status ist ein bedeutender Meilenstein für das NanoKnife-System und hebt den Wert von AngioDynamics’ strategischen Investitionen in IRE-Technologie hervor.
- Received CPT® Category I codes for IRE treatment of prostate and liver lesions
- New codes will facilitate reimbursement for healthcare providers
- Expands market access to the NanoKnife System for patients
- Recognition under Category I codes follows rigorous clinical studies and peer-reviewed data
- Potential for broader insurance coverage and defined reimbursement rates
- New codes will not be effective until January 1, 2026
Insights
The AMA's granting of Category I CPT codes for Irreversible Electroporation (IRE) in prostate and liver treatments is a significant development for AngioDynamics. This decision will likely improve reimbursement for healthcare providers using the NanoKnife System, potentially increasing adoption and expanding market access.
The NanoKnife System's IRE technology offers unique advantages over traditional surgery or thermal ablation, including the ability to treat all organ segments with precise margins while preserving nerve and blood vessel architecture. This could lead to fewer side effects and improved patient outcomes.
However, it's important to note that the new codes won't be effective until January 1, 2026, which means the financial impact may not be immediate. Investors should consider this long-term potential against the company's current financial position and market performance.
This development is positive for AngioDynamics' long-term prospects. The CPT Category I codes should lead to improved reimbursement rates and broader insurance coverage for NanoKnife procedures, potentially driving revenue growth in the coming years.
However, with a current market cap of
In the interim, focus should be on AngioDynamics' ability to manage costs, drive adoption of the NanoKnife System and prepare for increased demand once the new codes are in effect. The company's cash position and burn rate will be important metrics to watch as they invest in this opportunity while awaiting the potential revenue boost.
New Codes Expand Market Access to Treatment with the NanoKnife® System
The decision by the American Medical Association’s (“AMA”) CPT® Editorial Panel will facilitate reimbursement for healthcare providers performing IRE ablation procedures and enables broader access to the NanoKnife System for patients. The new codes will be effective, with physician Relative Value Units (RVUs) attached, on January 1, 2026.
The NanoKnife System utilizes IRE technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This minimally invasive treatment offers unique advantages over traditional surgery or thermal ablation techniques enabling physicians to treat all segments of an organ, with precise treatment margins, and a lower likelihood of side effects due to its preservation of nerve and blood vessel architecture.1,2,3
“Achieving CPT® Category I status is a significant milestone for the NanoKnife System and underscores our commitment to providing innovative and effective treatment options for patients,” said Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. “This achievement highlights the value of AngioDynamics' strategic investments in our innovative NanoKnife System and IRE technology. With CPT® Category I codes now established for prostate and liver lesions, we will continue to work to expand patient access to these life-changing treatments.”
With these new CPT® Category I codes, healthcare providers will be able to bill more precisely for the treatments provided and should achieve broader insurance coverage and defined reimbursement rates for NanoKnife procedures, increasing market access to this minimally invasive IRE technology.
The CPT® Category I codes are reserved for services and procedures that have demonstrated clinical efficacy, widespread use, and proven value in the medical community. The recognition of Irreversible Electroporation under these codes follows rigorous clinical studies and peer-reviewed data using the NanoKnife System that met the requirements for Category I CPT® codes.
About the NanoKnife System
The NanoKnife System utilizes Irreversible Electroporation (IRE) technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This stimulus induces an apoptotic-like cellular death in the targeted tissue, resulting in a complete ablation of the targeted tissue.4 Visit nanoknife.com for full product information.
About AngioDynamics, Inc.
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life.
The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.
Safe Harbor
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign healthcare reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2024. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
In
AngioDynamics, the AngioDynamics logo, and NanoKnife are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. All other trademarks are the property of their respective owners. ©2024 AngioDynamics, Inc
______________________________
1 Faiella E, Santucci D, D'Amone G, et al. Focal minimally invasive treatment in localized prostate cancer: comprehensive review of different possible strategies. Cancers (
2 Scheltema MJ, Geboers B, Blazevski A, et al. Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer. BJU Int. 2023;131 Suppl 4:6-13. doi:10.1111/bju.15946
3 Lee EW, Thai S, Kee ST. Irreversible electroporation: a novel image-guided cancer therapy. Gut Liver. 2010;4 Suppl 1(Suppl 1):S99-S104. doi:10.5009/gnl.2010.4.S1.S99
4 Lee EW, Thai S, Kee ST. Irreversible electroporation: a novel image-guided cancer therapy. Gut Liver. 2010;4 Suppl 1(Suppl 1):S99-S104. doi:10.5009/gnl.2010.4.S1.S99
View source version on businesswire.com: https://www.businesswire.com/news/home/20241017440579/en/
Investor Contact:
Stephen Trowbridge
Executive Vice President & CFO
518-795-1408
strowbridge@angiodynamics.com
Media Contact:
Saleem Cheeks
Vice President, Communications
518-795-1174
scheeks@angiodynamics.com
Source: AngioDynamics, Inc.
FAQ
What did AngioDynamics (ANGO) announce regarding CPT codes for IRE?
How will the new CPT Category I codes benefit AngioDynamics (ANGO)?
What is the NanoKnife System used by AngioDynamics (ANGO)?
When will the new CPT Category I codes for AngioDynamics' (ANGO) IRE treatments become effective?
